FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Andere talen Frazier Lifesciences Acquisition Corporation

Aandelen

NAMS

NL00150012L7

Geschatte realtime Tradegate Andere beurzen 08:00:15 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
21,2 ^EUR	-3,50%		+2,47%	+96,69%

09/04	NewAmsterdam Pharma Company N.V. neemt meer dan 9.000 patiënten op in de pivotale Fase 3 Prevail Global Cardiovascular Outcome Trial waarin het effect van Obicetrapib wordt geëvalueerd bij patiënten met gevestigde atherosclerotische hart- en vaatziekten	CI
01/04	NewAmsterdam Pharma benoemt Juliette Audet tot Chief Business Officer	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	27/03
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	25/03
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	12/03
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	12/03
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops	28/02
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	26/02
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	26/02
NewAmsterdam Pharma Prices $175.3 Million Public Offering	14/02
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	14/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Frazier Lifesciences Acquisition Corporation

Aandelen

NAMS

NL00150012L7

Andere talen

Filters